Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2024 According to an ASLAN Pharmaceuticals media release, the company is now enrolling patients in US sites are according to the updated criteria and additional sites in Europe are on track to open in the first half of 2024.
27 Oct 2023 According to an ASLAN Pharmaceuticals media release, the company is conducting continued analyses of this study and plans to submit data on biomarkers and patient reported outcomes for publication at a future scientific congress.
27 Oct 2023 Results presented in an ASLAN Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com